6- (4- (3- (methylsulfonyl)benzylamino)- 5- (trifluoromethyl)pyrimidin- 2- ylamino)- 3,4- dihydroquinolin- 2(1H)- one

09/01/2016 - "The aim of this study was to evaluate the effects of PF573,228 on the cells derived from mouse vascular tumors, namely, endothelioma cells. "
01/01/2018 - "Interestingly, 3D-tumor organoids derived from autochthonous KC (Kras;PdxCre) mice treated with PF-573228 revealed a significant decrease in tumor organoid size and increase in organoid cell death. "
09/01/2016 - "Since all the processes inhibited by PF573,228 provide important support to tumor survival and progression, the drug may have a potential role in the treatment of vascular tumors. "
09/01/2016 - "PF573,228 inhibits vascular tumor cell growth, migration as well as angiogenesis, induces apoptosis and abrogates PRAS40 and S6RP phosphorylation."
11/01/2009 - "Small molecule inhibitors (PF-573,228; PF-562,271 and NVP-226) for use as potential cancer therapies have been developed. "

11/07/2011 - "Electrophysiological studies of PF573228 actions on ion currents were performed in pituitary tumor (GH(3)) cells, in GH(3) cells transfected with K(Ca)1.1 siRNAs and in human embryonic kidney (HEK) cells expressing α-human slowpoke (α-hSlo). "

11/01/2018 - "Attenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase."

11/01/2018 - "Finally, in a murine ALI model induced by LPS (1.25 mg/ml, IT), rescue treatment with PF-228 was associated with significantly reduced lung injury. "

02/01/2014 - "In vivo, inhalation of FAK-siRNA (n=5) or oral delivery of PF-228 (FAK inhibitor PF-573 228; n=5) inhibited rat monocrotaline induced PAH, improving the haemodynamics, vascular remodelling (media thickness), and right ventricular hypertrophy. "